Cellumen
Latest round
- Series B
Last raised
- Feb 2009
Total raised
- $9.5M
Investors
- 3
About Cellumen
Based in Pennsylvania, US, and founded in 2004 by CEO Lansing Taylor, Cellumen, Inc. provides a cellular systems biology solution that provides accurate predictions of drug efficacy and safety. In August 2010, Cellumen was acquired by Apredica (Cyprotex). The company's flagship offering, CellCiphr, includes a suite of advanced reagents and assays designed to measure and manipulate cell function. The products are used for profiling cellular models of disease and toxicity, enabling better lead generation, the identification of toxic liabilities early in the discovery process, and improved patient stratification.
Who invested in Cellumen
3 investors across 3 rounds
See all investors in Cellumen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cellumen
Who invested in Cellumen?
Cellumen has 3 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cellumen raised?
Cellumen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cellumen last raise money?
Cellumen's most recent round on record is a Series B, in Feb 2009.
What does Cellumen do?
Based in Pennsylvania, US, and founded in 2004 by CEO Lansing Taylor, Cellumen, Inc.
Where is Cellumen headquartered?
Cellumen is headquartered in Pittsburgh, US.
Which VCs invest in companies like Cellumen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Cellumen's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Cellumen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.